UnitedHealth Group Incorporated · UNH · FY2026 Q2 · Calendar Q3 2026

UNH Q2 2026: EPS Beat, Guidance Raised as AI and Cost Trends Improve

UnitedHealth Group delivered a decisive Q2 2026 beat, with adjusted EPS of $6.38 exceeding consensus by 29%, alongside a $112B revenue print and a 55% rise in operating earnings. The company raised full-year EPS guidance to $19.50-$20, reflecting improving Medicare Advantage cost trends and accelerating AI-driven operational efficiencies. Commercial cost trends remain elevated above 11% and Medicaid margins stay constrained, but management's confident tone, expanded capital return ($5B buybacks, dividend hike to $9.28), and the closed Alegeus combination signal conviction in the forward trajectory.

Reported Before market openNYSEHealthcare $379.28B market cap
100quality score

Company context

Snapshot as of publication

UnitedHealth Group Incorporated (UNH) operates as a comprehensive healthcare enterprise across the United States, structuring its diverse services into four key divisions: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. The UnitedHealthcare segment provides a wide array of health benefit plans and consumer-focused services. These offerings cater to a broad spectrum of clients, including large national corporations, public sector employers, mid-sized and small businesses, and individual consumers. It also delivers specialized health coverage and wellness programs tailored for individuals aged 50 and older, addressing their needs for preventive and acute care, chronic disease management, and other age-specific health issues. This division further encompasses Medicaid plans, children's health insurance, dental benefits, and various hospital and clinical services. Optum Health focuses on delivering direct healthcare solutions and management services.…

Earnings scorecard

Reported versus consensus
Reported EPS $6.38 Consensus $5
EPS surprise +29.1% Reported versus consensus
Reported revenue $112.03B Consensus $110.81B
Revenue surprise +1.1% Reported versus consensus

Market reaction

prior-close to event-session close
Stock move +1.2% Event window
SPY move -0.5% Same window
Abnormal move +1.7% Stock minus SPY
Volume 2.2× Versus trailing sessions
Subsequent drift -1.4% Up to 20 sessions
UNHSPY benchmark

Follow UNH with an agent that reads every filing, transcript, and price print. Free to start.

Try FN2 free

Transcript intelligence

What changed

Q2 2026 adjusted EPS came in at $6.38 versus consensus $4.94, a 29.1% surprise. Revenue of $112.0B beat estimates by 1.1%. Operating earnings rose 55% year over year. Medicare Advantage medical cost trends came in below company expectations, while commercial cost trends remained above 11%. Management raised FY2026 adjusted EPS guidance to $19.50-$20 from a prior outlook above $18.25, and increased operating earnings targets for UnitedHealthcare and Optum Health. Share repurchases were accelerated to $5B for the year, and the dividend was raised to $9.28 per share. AI adoption reached 70% of employed clinicians with a target of >90% by year-end. The Alegeus Technologies combination closed on July 2. The stock's abnormal move on the report day was +1.70% versus a benchmark decline of -0.54%, on 2.22x baseline volume, with a subsequent drift of -1.36%.

Guidance delta

Guidance was raised. FY2026 adjusted EPS outlook lifted to $19.50-$20 from the prior 'above $18.25' level reaffirmed in Q1 2026. Operating earnings outlook increased for both UnitedHealthcare and Optum Health. Share repurchases accelerated from $2B planned by Q2 to $5B for the full year. Dividend raised to $9.28 per share. The company reaffirmed its long-term 13-16% growth ambition.

Key takeaways

  • Adjusted EPS of $6.38 beat consensus by 29.1%; revenue of $112.0B beat by 1.1%. Operating earnings rose 55% year over year.
  • FY2026 EPS guidance raised to $19.50-$20, with higher operating earnings targets for UnitedHealthcare and Optum Health.
  • Medicare Advantage cost trends came in below company expectations; commercial cost trends remained above 11%.
  • Optum Health achieved ~10% reduction in hospitalizations in targeted regions and expanded rural home-visit capacity to 2.5M visits.
  • AI adoption at 70% of employed clinicians, targeting >90% by year-end, driving claims, prior-auth, and documentation efficiencies.
  • Share repurchases accelerated to $5B; dividend raised to $9.28 per share.

Management priorities

  • Scale AI ambient listening and clinical documentation tools to >90% of providers by year-end.
  • Eliminate 30% of prior-authorization volume and two-thirds of pediatric prior-authorizations by year-end.
  • Expand Optum Health's home-based and rural care programs across the footprint by end-2026.
  • Commercialize AI-enabled products (Value Connect, digital prior auth) to external customers.
  • Execute $5B in share repurchases and the raised dividend.
  • Plan 2027 benefits with early payer collaboration and refined risk-adjusted pricing.

Related earnings events

Healthcare
JNJ · FY2026 Q2 · Calendar Q3 2026JNJ Q2 2026: $25.3B Sales, Guidance Raised to $101.1B Midpoint, New Launches Drive Growth

Sources

  1. Earnings call transcript and parsed analysis · 2026-07-16T15:03:11.416641+00:00
  2. FN2 earnings calendar · 2026-07-28T01:23:15.070317+00:00
  3. Polygon adjusted daily market bars · 2026-07-28T08:21:58.241886+00:00
  4. Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-07-28T08:21:58.239517+00:00

Methodology

Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.

Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.

By FN2 Research · Updated . For educational purposes only; not investment advice.